Vir Biotechnology VIR Stock
Vir Biotechnology Price Chart
Vir Biotechnology VIR Financial and Trading Overview
| Vir Biotechnology stock price | 4.66 USD |
| Previous Close | 26.02 USD |
| Open | 25.89 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 25.59 - 26.04 USD |
| 52 Week Range | 18.05 - 31.78 USD |
| Volume | 642.05K USD |
| Avg. Volume | 857.6K USD |
| Market Cap | 3.48B USD |
| Beta (5Y Monthly) | 0.255044 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.23 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.71 USD |
VIR Valuation Measures
| Enterprise Value | 1.36B USD |
| Trailing P/E | N/A |
| Forward P/E | -5.2912426 |
| PEG Ratio (5 yr expected) | -0.89 |
| Price/Sales (ttm) | 7.7991514 |
| Price/Book (mrq) | 1.7655454 |
| Enterprise Value/Revenue | 3.058 |
| Enterprise Value/EBITDA | -4.944 |
Trading Information
Vir Biotechnology Stock Price History
| Beta (5Y Monthly) | 0.255044 |
| 52-Week Change | 5.91% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 31.78 USD |
| 52 Week Low | 18.05 USD |
| 50-Day Moving Average | 25.26 USD |
| 200-Day Moving Average | 24.59 USD |
VIR Share Statistics
| Avg. Volume (3 month) | 857.6K USD |
| Avg. Daily Volume (10-Days) | 736.72K USD |
| Shares Outstanding | 133.98M |
| Float | 86.5M |
| Short Ratio | 6.51 |
| % Held by Insiders | 14.24% |
| % Held by Institutions | 73.82% |
| Shares Short | 5.58M |
| Short % of Float | 7.04% |
| Short % of Shares Outstanding | 4.16% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -32.19% |
| Operating Margin (ttm) | -64.29% |
| Gross Margin | -26.13% |
| EBITDA Margin | -61.85% |
Management Effectiveness
| Return on Assets (ttm) | -6.45% |
| Return on Equity (ttm) | -7.23% |
Income Statement
| Revenue (ttm) | 446.3M USD |
| Revenue Per Share (ttm) | 3.36 USD |
| Quarterly Revenue Growth (yoy) | -94.89% |
| Gross Profit (ttm) | 1.03B USD |
| EBITDA | -276062016 USD |
| Net Income Avi to Common (ttm) | -143684000 USD |
| Diluted EPS (ttm) | -1.06 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.25B USD |
| Total Cash Per Share (mrq) | 16.8 USD |
| Total Debt (mrq) | 128.73M USD |
| Total Debt/Equity (mrq) | 6.53 USD |
| Current Ratio (mrq) | 4.86 |
| Book Value Per Share (mrq) | 14.715 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 987.38M USD |
| Levered Free Cash Flow (ttm) | 853.38M USD |
Profile of Vir Biotechnology
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 499 Illinois Street |
| ZIP | 94158 |
| Phone | 415 906 4324 |
| Website | https://www.vir.bio |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 576 |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Q&A For Vir Biotechnology Stock
What is a current VIR stock price?
Vir Biotechnology VIR stock price today per share is 4.66 USD.
How to purchase Vir Biotechnology stock?
You can buy VIR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vir Biotechnology?
The stock symbol or ticker of Vir Biotechnology is VIR.
Which industry does the Vir Biotechnology company belong to?
The Vir Biotechnology industry is Biotechnology.
How many shares does Vir Biotechnology have in circulation?
The max supply of Vir Biotechnology shares is 138.24M.
What is Vir Biotechnology Price to Earnings Ratio (PE Ratio)?
Vir Biotechnology PE Ratio is now.
What was Vir Biotechnology earnings per share over the trailing 12 months (TTM)?
Vir Biotechnology EPS is -4.23 USD over the trailing 12 months.
Which sector does the Vir Biotechnology company belong to?
The Vir Biotechnology sector is Healthcare.
Vir Biotechnology VIR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 19199.16 USD — |
+2.47
|
8.02B USD — | 18961.69 USD — | 19210.95 USD — | — - | 8.02B USD — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2996.92 USD — |
+2
|
— — | 2962.78 USD — | 2997.07 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4122.62 USD — |
+0.93
|
— — | 4112.46 USD — | 4152.13 USD — | — - | — — |
| Nasdaq Health Care IXHC | 946.2 USD — |
+1.52
|
— — | 941.18 USD — | 951.02 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 9395.24 USD — |
+2.49
|
— — | 9276.81 USD — | 9400.1 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1351.02 USD — |
+1.45
|
— — | 1340.65 USD — | 1354.05 USD — | — - | — — |
- {{ link.label }} {{link}}